Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 634 | 108 | 512 |
| Samples | 437 | 86 | 343 |
| Peptides | 371 | 58 | 313 |
Function
WDR19 · WD repeat domain 19
The protein encoded by this gene is a member of the WD (tryptophan-aspartic acid) repeat family, which is a large family of structurally-related proteins known to participate in a wide range of cellular processes. Each WD repeat typically contains about 40 amino acids that are usually bracketed by glycine-histidine and tryptophan-aspartic acid (WD) dipeptides. This protein contains six WD repeats, three transmembrane domains, and a clathrin heavy-chain repeat. Mutations in this gene have been described in individuals with a wide range of disorders affecting function of the cilium. These disorders are known as ciliopathies, and include Jeune syndrome, Sensenbrenner syndromes, Senior-Loken syndrome, combined or isolated nephronophthisis (NPHP), and retinitis pigmentosa (RP). Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2015].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 361 amino-acid changes on canonical ENST00000399820 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in WDR19 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in WDR19 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 4/26 15% | 0/0 0% |
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Chordoma | 2/7 29% | 0/13 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 19/612 3% |
| Melanoma | 13/210 6% | 52/1899 3% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 16/1390 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Thyroid Gland Carcinoma | 4/45 9% | 20/1592 1% |
| Colorectal Carcinoma | 8/143 6% | 41/3239 1% |
| Other Solid Cancers | 2/94 2% | 20/1515 1% |
| Gastric Carcinoma | 3/74 4% | 22/1809 1% |
| Cervical Carcinoma | 2/35 6% | 4/422 1% |
| Other Sarcomas | 3/69 4% | 5/699 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Head and Neck Carcinoma | 1/85 1% | 15/1574 1% |
| Bladder Carcinoma | 0/58 0% | 9/956 1% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
| Non-Cancerous | 0/104 0% | 8/830 1% |
| Hepatocellular Carcinoma | 2/46 4% | 16/2210 1% |
| Glioma | 0/52 0% | 17/2127 1% |
| Esophageal Carcinoma | 1/23 4% | 5/769 1% |
| Biliary Tract Carcinoma | 0/54 0% | 7/950 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 5/810 1% |
| Kidney Carcinoma | 3/85 4% | 8/1862 0% |
| Neuroendocrine Tumour | 3/154 2% | 1/577 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 14/2550 1% |
| Ovarian Carcinoma | 2/109 2% | 4/998 0% |
| Breast Carcinoma | 4/144 3% | 14/3264 0% |
Mutation Distribution
Where WDR19 is mutated · all tissues, split by cell line vs tissue
How many mutations in WDR19 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 634 mutations in WDR19
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|